218 related articles for article (PubMed ID: 21654628)
1. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Vera JF; Rooney CM; Leen AM
J Vis Exp; 2011 May; (51):. PubMed ID: 21654628
[TBL] [Abstract][Full Text] [Related]
2. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
3. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
[TBL] [Abstract][Full Text] [Related]
4. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
Sili U; Leen AM; Vera JF; Gee AP; Huls H; Heslop HE; Bollard CM; Rooney CM
Cytotherapy; 2012 Jan; 14(1):7-11. PubMed ID: 22172091
[TBL] [Abstract][Full Text] [Related]
5. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
Gerdemann U; Christin AS; Vera JF; Ramos CA; Fujita Y; Liu H; Dilloo D; Heslop HE; Brenner MK; Rooney CM; Leen AM
Mol Ther; 2009 Sep; 17(9):1616-25. PubMed ID: 19584818
[TBL] [Abstract][Full Text] [Related]
6. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
[TBL] [Abstract][Full Text] [Related]
7. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
8. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
Gerdemann U; Keirnan JM; Katari UL; Yanagisawa R; Christin AS; Huye LE; Perna SK; Ennamuri S; Gottschalk S; Brenner MK; Heslop HE; Rooney CM; Leen AM
Mol Ther; 2012 Aug; 20(8):1622-32. PubMed ID: 22801446
[TBL] [Abstract][Full Text] [Related]
9. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
[TBL] [Abstract][Full Text] [Related]
12. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.
Hanley PJ; Lam S; Shpall EJ; Bollard CM
J Vis Exp; 2012 May; (63):e3627. PubMed ID: 22588077
[TBL] [Abstract][Full Text] [Related]
13. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
14. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
15. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
Savoldo B; Cubbage ML; Durett AG; Goss J; Huls MH; Liu Z; Teresita L; Gee AP; Ling PD; Brenner MK; Heslop HE; Rooney CM
J Immunol; 2002 Jan; 168(2):909-18. PubMed ID: 11777989
[TBL] [Abstract][Full Text] [Related]
16. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.
Jiang W; Withers B; Sutrave G; Clancy LE; Yong MI; Blyth E
Curr Hematol Malig Rep; 2019 Aug; 14(4):247-260. PubMed ID: 31228095
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
[TBL] [Abstract][Full Text] [Related]
18. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
19. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program.
Withers B; Clancy L; Burgess J; Simms R; Brown R; Micklethwaite K; Blyth E; Gottlieb D
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2433-2442. PubMed ID: 30172015
[TBL] [Abstract][Full Text] [Related]
20. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
